Recognises the human Egl nine homolog 2 (EGLN2) protein, an important oxygen sensor
Anti-EGLN2/PHD1 antibody (crb2005163)
Western blot analysis of whole cell extract of human osteocarcinoma (U-2 OS) and HeLa cells (20µg).
Lane 1: U-2 OS cells with GFP overexpression
Lane 2: U-2 OS cells with GFP-PHD1 overexpression
Lane 3: HeLa cells transfected with control siRNA.
Lane 4: HeLa cells transfected with siPHD1.
Western blot image provided courtesy of Prof. Sonia Rocha
|Antigen Peptide||KLH conjugated synthetic peptide crb1200422e|
|Protein ID||Uniprot ID: Q96KS0|
|Aliases||Egl nine homolog 2, EGLN2 Isoform p43, EGLN2 Isoform p40, Prolyl hydroxylase domain-containing protein 1, PHD1, Hypoxia-inducible factor prolyl hydroxylase 1, HIF-PH1, HPH-1|
|Target Protein Species||Human|
|Validation||WB (1:1000 in 2% BSA), ELISA (1:1000)|
|Storage Stabilisers||The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.|
|Storage||The product should be stored at -20°C for for short term storage and long term storage. Avoid repeated freeze/ thaw cycles.|
Zhang, R., Lai, L., He, J., Chen, C., You, D., Duan, W., Dong, X., Zhu, Y., Lin, L., Shen, S., Guo, Y., Su, L., Shafer, A., Moran, S., Fleischer, T., Bjaanæs, M., Karlsson, A., Planck, M., Staaf, J., Helland, Å., Esteller, M., Wei, Y., Chen, F. and Christiani, D. (2019). EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC. Epigenetics, 14(2), 118-129. PMID: 30665327
Zhang, J., Wang, C., Chen, X., Takada, M., Fan, C., Zheng, X., Wen, H., Liu, Y., Wang, C., Pestell, R., Aird, K., Kaelin, W., Liu, X. and Zhang, Q. (2015). EglN2 associates with the NRF1‐PGC1α complex and controls mitochondrial function in breast cancer. EMBO J, 34(23), 2953-2970. PMID: 26492917
The human Egl nine homolog 2 (EglN2)/prolyl hydroxylase domain-containing enzyme (PHD1) is an important oxygen sensor and is responsible for the oxygen-dependent degradation and hydroxylation of hypoxia‐inducible factors (HIFs). HIFs are transcription factors that respond to decreases in available oxygen in the cellular environment (hypoxia). In the presence of oxygen EglN2/PHD1 hydroxylates HIFα subunits on conserved prolines within the oxygen-dependent degradation (ODD) domain, targeting them for degradation. Under hypoxic conditions, EglNs lose their ability to hydroxylate HIFα subunits leading to HIFα stabilisation and dimerization with HIF1β (ARNT). Dimerization activates transcription of many genes linked to hypoxic adaptation, such those involved in cell proliferation, metabolism, and angiogenesis.
Due to their role in hypoxia, EglNs contribute to tumourigenesis. EglN2 mRNA levels are higher in several cancers for example in oestrogen receptor-α (ERα) positive breast cancer compared to ERα‐negative breast cancer. Depleting EglN2 decreases cell proliferation in breast cancer models by diminishing cyclin D1 transcription.